Physician profile
Anton Bahu
NPI 1366412272
$1,333.16
in general payments reported to CMS, 2019-2025
27 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $226 · 2020: $242 · 2021: $177 · 2022: $276 · 2023: $192 · 2024: $219.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $412.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $411.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $192.86 | 2019-2023 | |
| Astrazeneca Pharmaceuticals Lp | $126.22 | 2022-2024 | Breztri, Seroquel, Airsupra |
| Glaxosmithkline, LLC. | $95.42 | 2021-2024 | Trelegy Ellipta, Arexvy, Shingrix |
| Janssen Pharmaceuticals, INC | $91.77 | 2019-2020 | |
| Abbvie INC. | $85.37 | 2021-2022 | |
| Lilly USA, LLC | $70.27 | 2019-2023 | Jardiance |
| Amgen INC. | $67.01 | 2021-2023 | Repatha, Otezla |
| Exact Sciences Corporation | $65.84 | 2023-2024 | Cologuard Collection Kit |
| Sunovion Pharmaceuticals INC. | $55.95 | 2019 | |
| Novartis Pharmaceuticals Corporation | $48.67 | 2020-2022 | |
| Abbott Laboratories | $46.77 | 2022 | |
| Allergan, INC. | $45.20 | 2020 | |
| Otsuka America Pharmaceutical, INC. | $43.59 | 2023-2024 | Rexulti |
| Teva Pharmaceuticals USA, INC. | $37.36 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $33.42 | 2021-2024 | Jardiance |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $28.75 | 2019-2021 | |
| Esperion Therapeutics, INC. | $23.40 | 2024 | Nexletol |
| Avanir Pharmaceuticals, INC. | $23.37 | 2020 | |
| Phathom Pharmaceuticals, INC. | $21.64 | 2023 | Voquezna |
| Janssen Biotech, INC. | $21.39 | 2023 | Stelara |
| Sk Life Science, INC. | $19.23 | 2022 | |
| Boston Scientific Corporation | $18.44 | 2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $16.89 | 2021 | |
| Genentech USA, INC. | $16.66 | 2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $13.56 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $12.41 | 2022 | |
| Lundbeck LLC | $11.70 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anton Bahu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.